Semin intervent Radiol 2011; 28(3): 333-338
DOI: 10.1055/s-0031-1284460
© Thieme Medical Publishers

Balloon-occluded Retrograde Transvenous Obliteration (BRTO): Technical Results and Outcomes

Wael E. A. Saad1 , Saher S. Sabri1
  • 1Division of Vascular Interventional Radiology, Department of Radiology, University of Virginia Health System, Charlottesville, Virginia
Further Information

Publication History

Publication Date:
15 August 2011 (online)

ABSTRACT

Variceal bleeding is one of the major complications of portal hypertension. Gastric variceal (GV) bleeding is less common than esophageal variceal (EV) bleeding, however, is associated with a high morbidity and mortality. Balloon-occluded retrograde transvenous obliteration (BRTO) is an established procedure for the management of gastric varices in Japan and has shown promising results in the past decade. The technical success rate, intent-to-treat (including technically failed BRTO-procedures) obliteration rate, and the obliteration rate of gastric varices of technically successful BRTO procedures was 91% (79–100%), 86% (73–100%), and 94% (75–100), respectively. BRTO is successful in controlling active gastric variceal bleeding in 95% of cases (91–100%) and in significantly reducing or resolving encephalopathy in 100% of cases. However, BRTO diverts blood into the portal circulation and increases the portal hypertension, thus aggravating esophageal varices with their potential for bleeding. The 1-, 2-, and 3-year esophageal variceal aggravation rates are 27–35%, 45–66%, and 45–91%, respectively. The gastric variceal rebleed rate of successful BRTO procedures, the intent-to-treat gastric variceal rebleed rate, and the global (all types of varices) variceal rebleed rate are 3.2–8.7%, 10–20%, and 19–31%, respectively. However, the advantage of diverting blood into the portal circulation and potentially toward the liver is improved hepatic function and possible patient survival. Unfortunately, the improved hepatic function is transient (for 6–12 months); however, it is preserved in the long-term (1–3 years). Patient 1-, 2-, 3-, and 5-year survival rates are 83–98%, 76–79%, 66–85%, and 39–69%, respectively. Patient survival is determined by baseline hepatic reserve and the presence of hepatocellular carcinoma.

REFERENCES

  • 1 Hong C H, Kim H J, Park J H et al.. Treatment of patients with gastric variceal hemorrhage: endoscopic N-butyl-2-cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration.  J Gastroenterol Hepatol. 2009;  24 (3) 372-378
  • 2 Ryan B M, Stockbrugger R W, Ryan J M. A pathophysiologic, gastroenterologic, and radiologic approach to the management of gastric varices.  Gastroenterology. 2004;  126 (4) 1175-1189
  • 3 Hirota S, Matsumoto S, Tomita M, Sako M, Kono M. Retrograde transvenous obliteration of gastric varices.  Radiology. 1999;  211 (2) 349-356
  • 4 Kitamoto M, Imamura M, Kamada K et al.. Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage.  AJR Am J Roentgenol. 2002;  178 (5) 1167-1174
  • 5 Sarin S K, Lahoti D, Saxena S P, Murthy N S, Makwana U K. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients.  Hepatology. 1992;  16 (6) 1343-1349
  • 6 Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy.  J Vasc Interv Radiol. 2001;  12 (3) 327-336
  • 7 Trudeau W, Prindiville T. Endoscopic injection sclerosis in bleeding gastric varices.  Gastrointest Endosc. 1986;  32 (4) 264-268
  • 8 Korula J, Chin K, Ko Y, Yamada S. Demonstration of two distinct subsets of gastric varices. Observations during a seven-year study of endoscopic sclerotherapy.  Dig Dis Sci. 1991;  36 (3) 303-309
  • 9 Oho K, Iwao T, Sumino M, Toyonaga A, Tanikawa K. Ethanolamine oleate versus butyl cyanoacrylate for bleeding gastric varices: a nonrandomized study.  Endoscopy. 1995;  27 (5) 349-354
  • 10 Kim H G, Han K H, Lee C Y et al.. Outcome of endoscopic injection therapy of histoacryl in bleeding gastric varices.  Gastroenterology. 1998;  114 A1273
  • 11 Rockey D C. Management of gastric varices.  Gastroenterology. 2001;  120 (7) 1875-1876 discussion 1876-1877
  • 12 Kiyosue H, Mori H, Matsumoto S, Yamada Y, Hori Y, Okino Y. Transcatheter obliteration of gastric varices. Part 1. Anatomic classification.  Radiographics. 2003;  23 (4) 911-920
  • 13 Kiyosue H, Mori H, Matsumoto S, Yamada Y, Hori Y, Okino Y. Transcatheter obliteration of gastric varices: Part 2. Strategy and techniques based on hemodynamic features.  Radiographics. 2003;  23 (4) 921-937 discussion 937
  • 14 Ibukuro K, Sugihara T, Tanaka R et al.. Balloon-occluded retrograde transvenous obliteration (BRTO) for a direct shunt between the inferior mesenteric vein and the inferior vena cava in a patient with hepatic encephalopathy.  J Vasc Interv Radiol. 2007;  18 (1 Pt 1) 121-125
  • 15 Ninoi T, Nishida N, Kaminou T et al.. Balloon-occluded retrograde transvenous obliteration of gastric varices with gastrorenal shunt: long-term follow-up in 78 patients.  AJR Am J Roentgenol. 2005;  184 (4) 1340-1346
  • 16 Akahoshi T, Hashizume M, Tomikawa M et al.. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience.  J Gastroenterol Hepatol. 2008;  23 (11) 1702-1709
  • 17 Cho S K, Shin S W, Lee I H et al.. Balloon-occluded retrograde transvenous obliteration of gastric varices: outcomes and complications in 49 patients.  AJR Am J Roentgenol. 2007;  189 (6) W365-W372
  • 18 Kumamoto M, Toyonaga A, Inoue H et al.. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome.  J Gastroenterol Hepatol. 2010;  25 (6) 1129-1135
  • 19 Chikamori F, Kuniyoshi N, Shibuya S, Takase Y. Eight years of experience with transjugular retrograde obliteration for gastric varices with gastrorenal shunts.  Surgery. 2001;  129 (4) 414-420
  • 20 Kanagawa H, Mima S, Kouyama H et al.. A successfully treated case of fundic varices by retrograde transvenous obliteration with balloon.  Jpn J Gastroenterol. 1991;  88 1452-1462
  • 21 Kanagawa H, Mima S, Kouyama H, Gotoh K, Uchida T, Okuda K. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration.  J Gastroenterol Hepatol. 1996;  11 (1) 51-58
  • 22 de Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis.  Clin Liver Dis. 2001;  5 (3) 645-663
  • 23 Hayashi S, Saeki S, Hosoi H et al.. A clinical and portal hemodynamic analysis for obliteration of gastric-renal shunt communicated with gastric fundic varices.  Nippon Shokakibyo Gakkai Zasshi. 1998;  95 (7) 755-763
  • 24 Tanihata H, Minamiguchi H, Sato M et al.. Changes in portal systemic pressure gradient after balloon-occluded retrograde transvenous obliteration of gastric varices and aggravation of esophageal varices.  Cardiovasc Intervent Radiol. 2009;  32 (6) 1209-1216
  • 25 Choi Y S, Lee J H, Sinn D H et al.. Effect of balloon-occluded retrograde transvenous obliteration on the natural history of coexisting esophageal varices.  J Clin Gastroenterol. 2008;  42 (9) 974-979
  • 26 Nakamura S, Torii N, Yatsuji S et al.. Long-term follow up of esophageal varices after balloon-occluded retrograde transvenous obliteration for gastric varices.  Hepatol Res. 2008;  38 (4) 340-347
  • 27 Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T, Nishimura T. Infusion of 50% glucose solution before injection of ethanolamine oleate during balloon-occluded retrograde transvenous obliteration.  Australas Radiol. 2007;  51 (4) 334-338
  • 28 Ninoi T, Nakamura K, Kaminou T et al.. TIPS versus transcatheter sclerotherapy for gastric varices.  AJR Am J Roentgenol. 2004;  183 (2) 369-376
  • 29 Sonomura T, Sato M, Kishi K et al.. Balloon-occluded retrograde transvenous obliteration for gastric varices: a feasibility study.  Cardiovasc Intervent Radiol. 1998;  21 (1) 27-30
  • 30 Kiyosue H, Matsumoto S, Onishi R et al.. Balloon-occluded retrograde transvenous obliteration (B-RTO) for gastric varices: therapeutic results and problems.  Nippon Igaku Hoshasen Gakkai Zasshi. 1999;  59 (1) 12-19
  • 31 Koito K, Namieno T, Nagakawa T, Morita K. Balloon-occluded retrograde transvenous obliteration for gastric varices with gastrorenal or gastrocaval collaterals.  AJR Am J Roentgenol. 1996;  167 (5) 1317-1320
  • 32 Chikamori F, Kuniyoshi N, Kawashima T, Takase Y. Gastric varices with gastrorenal shunt: combined therapy using transjugular retrograde obliteration and partial splenic embolization.  AJR Am J Roentgenol. 2008;  191 (2) 555-559
  • 33 Chikamori F, Kuniyoshi N, Shibuya S, Takase Y. Transjugular retrograde obliteration for chronic portosystemic encephalopathy.  Abdom Imaging. 2000;  25 (6) 567-571
  • 34 Chikamori F, Kuniyoshi N, Shibuya S, Takase Y. Combination treatment of transjugular retrograde obliteration and endoscopic embolization for portosystemic encephalopathy with esophageal varices.  Hepatogastroenterology. 2004;  51 (59) 1379-1381
  • 35 Miyamoto Y, Oho K, Kumamoto M, Toyonaga A, Sata M. Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension.  J Gastroenterol Hepatol. 2003;  18 (8) 934-942
  • 36 Sugimori K, Morimoto M, Shirato K et al.. Retrograde transvenous obliteration of gastric varices associated with large collateral veins or a large gastrorenal shunt.  J Vasc Interv Radiol. 2005;  16 (1) 113-118
  • 37 Fukuda T, Hirota S, Matsumoto S et al.. Application of balloon-occluded retrograde transvenous obliteration to gastric varices complicating refractory ascites.  Cardiovasc Intervent Radiol. 2004;  27 (1) 64-67
  • 38 Shimoda R, Horiuchi K, Hagiwara S et al.. Short-term complications of retrograde transvenous obliteration of gastric varices in patients with portal hypertension: effects of obliteration of major portosystemic shunts.  Abdom Imaging. 2005;  30 (3) 306-313
  • 39 Takuma Y, Nouso K, Makino Y, Saito S, Shiratori Y. Prophylactic balloon-occluded retrograde transvenous obliteration for gastric varices in compensated cirrhosis.  Clin Gastroenterol Hepatol. 2005;  3 (12) 1245-1252
  • 40 Arai H, Abe T, Takagi H, Mori M. Efficacy of balloon-occluded retrograde transvenous obliteration, percutaneous transhepatic obliteration and combined techniques for the management of gastric fundal varices.  World J Gastroenterol. 2006;  12 (24) 3866-3873
  • 41 Arai H, Abe T, Shimoda R, Takagi H, Yamada T, Mori M. Emergency balloon-occluded retrograde transvenous obliteration for gastric varices.  J Gastroenterol. 2005;  40 (10) 964-971
  • 42 Choi Y H, Yoon C J, Park J H, Chung J W, Kwon J W, Choi G M. Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt.  Korean J Radiol. 2003;  4 (2) 109-116
  • 43 Park K S, Kim Y H, Choi J S et al.. Therapeutic efficacy of balloon-occluded retrograde transvenous obliteration in patients with gastric variceal bleeding.  Korean J Gastroenterol. 2006;  47 (5) 370-378
  • 44 Kim E S, Park S Y, Kwon K T et al.. The clinical usefulness of balloon occluded retrograde transvenous obliteration in gastric variceal bleeding.  Taehan Kan Hakhoe Chi. 2003;  9 (4) 315-323
  • 45 Matsumoto A, Hamamoto N, Nomura T et al.. Balloon-occluded retrograde transvenous obliteration of high risk gastric fundal varices.  Am J Gastroenterol. 1999;  94 (3) 643-649
  • 46 Park S J, Chung J W, Kim H-C, Jae H J, Park J H. The prevalence, risk factors, and clinical outcome of balloon rupture in balloon-occluded retrograde transvenous obliteration of gastric varices.  J Vasc Interv Radiol. 2010;  21 (4) 503-507
  • 47 Hassab M A. Gastroesophageal decongestion and splenectomy in the treatment of esophageal varices in bilharzial cirrhosis: further studies with a report on 355 operations.  Surgery. 1967;  61 (2) 169-176

Wael E. A. SaadM.D. F.S.I.R. 

Department of Radiology and Medical Imaging, University of Virginia Health System

Box 800170, 1215 Lee Street, Charlottesville, VA 22908

Email: wspikes@yahoo.com

    >